The National Electrical Manufacturers Association has published revised standards for positron emission tomography (PET), regardless of the scintillator used, which establishes methods of performance measurement on all currently available PET systems.
The National Electrical Manufacturers Association (NEMA) has published NEMA NU 2-2007 Performance Measurements of Positron Emission Tomographs. This revision includes standards for positron emission tomography (PET), regardless of the scintillator used, and establishes methods of performance measurement on all currently available PET systems. The new standards are more accurate at measuring scatter fraction and random coincidences than previous versions.
The major change since the last edition addresses an improvement in the inclusion of cameras with intrinsically radioactive components. Affected tests include count losses and randoms, as well as sensitivity. The spatial resolution measurement has been expanded to include the measurement and reporting of source position. Appendix A has been deleted.
According to Michael E. Casey, Ph.D., a member of the Coincidence Imaging Task Force chartered by the Nuclear Standards and Regulatory Committee, NEMA NU 2-2007 specifies methods that can be performed on all currently available PETs. "These include single and multiple slice, discrete and continuous detector, and time-of-flight instruments, as well as multi-planar and volume reconstruction models, dedicated PETs, and other coincidence-capable imaging systems," he said. "Wherever possible, future developments that could be readily anticipated were taken into account."
The committee has not specified methods that may be particularly appropriate for evaluating time-of-flight instruments, pending further evaluation of those instruments by the clinical and scientific communities.
Casey said that while this standard offers several advantages, it is the patient who gains the most. "A person undergoing a study benefits when a hospital or physician is able to compare tomographs from different manufactures to determine which best meets the needs of the patient," he said.
When the first standard was developed in the early 1990s, PET was a research instrument that focused primarily on the brain. During the 1990s, the focus shifted to clinical applications with the discovery that PET was an excellent tool for imaging cancer. The revised NEMA NU 2-2007 follows this trend and takes these applications into account. The focus of the standard has changed to highlight whole-body imaging.
The contents and scope of NEMA NU 2-2007 Performance Measurements of Positron Emission Tomographs may be viewed, or a hardcopy or electronic copy purchased for $64.00, by visiting NEMA's website at http://www.nema.org/stds/nu2.cfm
March 19, 2010, 11:10 am By Deepa FDG-PET for Vulvar Carcinoma DiagnosisPositron emission tomography (PET) can play a useful diagnostic role for patients with vulvar carcinoma, researchers said at the Society of Gynecologic Oncologists (SGO) 41st Annual Meeting on Women's...
March 19, 2010, 9:00 am By Deepa PET/CT for Detects Neuroendocrine Tumours MetastasesPET/CT Best Imaging Method for Detecting Neuroendocrine Tumours Metastases to the Heart, researchers presented at the 7th Annual European Neuroendocrine Tumor Society (ENETS) Conference. Read more....
March 17, 2010, 10:56 am By Deepa Alzheimer's Early Detection With PET ScanWestside Medical Associates of Los Angeles and Westside Medical Imaging (WMI) of Beverly Hills announce the benefit of early positron emission tomography (PET) scanning to identify Alzheimer's in its ...
March 15, 2010, 11:20 am By Deepa PET/CT Usage Rejected for Breast Cancer DiagnosesThe usage of positron emission tomography/ computer-assisted tomography (PET/CT) imaging was generally rejected for use in diagnosing breast cancer. Read more....
March 10, 2010, 9:49 am By Deepa FDG-PET May Identify Occult MetastasesA small phase 2 study suggests that 17-fluorodeoxyglucose positron-emission tomography (FDG-PET) may help identify occult masses after orchiectomy for stage 1 seminoma, said researchers here at the 20...